The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity

Human Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 342-346

  Suzuki, Hidenobu ^a   Gen, Keishi ^b  

^a Tanzawa Hospital   (Japan)

^b Seimo Hospital   (Japan)

Author keywords

Anti dopamine D 2 activity; Anti serotonin 5 HT2A activity; Blonanserin; Plasma concentration; Radioreceptor assay

Indexed keywords

BLONANSERIN; DOPAMINE; DOPAMINE 2 RECEPTOR; KETANSERIN; SEROTONIN; SEROTONIN 2A RECEPTOR; SPIPERONE; TRITIUM;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE; EVENING DOSAGE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AZIDES; BRAIN; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN;

EID: 77953924073     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1124     Document Type: Article

References (23)

1. Aoba A, Karita N, Yamaguchi N, et al. 1983. Electric convulsive therapy (ECT) increases plasma and blood cell haloperidol neuroleptic activities. Life Sci 33: 1797-1803.
2. Aoba A, Karita N, Yamaguchi N, et al. 1985. Absence age effect on plasma haloperidol neuroleptic levels in psychiatric patients. J Gerontol 40: 303-308.
3. Carlsson A, Lindqvist M. 1963. Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-144.
4. Castelao F, Ferreira L, Gelders YG, Heilen SLE. 1989. The efficacy of the D2 and 5-HT-2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophrenia Res 2: 411-415.
5. Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reintjens AJM, Janssen PAJ. 1985. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85: 329-332.
6. Dai D, Tang J, Rose R. 2001. Identification of variants of CYP 3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299: 825-831.
7. 2A) activity of risperidone, zotepine, and chlorpromazine - Is chlorpromazine an atypical antipsychotics? Jpn J Clin Phychopharmacol 5: 211-219.
8. 7 receptor research. Trends Pharmacol Sci 25: 481-486.
9. 2A antagonism. Jpn J Clin Phychopharmacol 11: 817-833.
10. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 489-796.
11. Kurumiya S, Une T. 2008. The research road to blonanserin, a new antipsychotic, and its pharmacological profile. Jpn J Clin Phychopharmacol 11: 807-815.
12. 3 receptor antagonists improve the learning performance in memory impaired rats. Psychopharmacology (Ber1) 179: 567-575.
13. Matsumoto K, Yasumoto K, Nakamura H, Terazawa Y. 2008. The effect of erythromycin on the pharmacokinetics and safety of blonanserin in healthy male Japanese. Jpn J Clin Phychopharmacol 11: 891-899.
14. Millan MJ. 2000. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295: 853-861.
15. Miura S. 2008. Clinical evaluation of blonanserin for schizophrenia - a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Phychopharmacol 11: 297-314.
16. Murasaki M. 2007. Clinical evaluation of blonanserin for schizophrenia - a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Phychopharmacol 10: 2059-2079.
17. Murasaki M. 2008. Preclinical and clinical features of blonanserin. Jpn J Clin Phychopharmacol 11: 855-868.
18. Murasaki M, Nishikawa H, Ishibashi T. 2008. Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn J Clin Phychopharmacol 11: 845-854.
19. Noda Y, Kurumiya S, Miura Y, Oka M. 1993. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocychoocta[b] pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side effects. J Pharmacol Exp Ther 265: 745-751.
20. Oka M, Noda Y, Ochi Y, et al. 1993. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264: 158-165.
21. Schotte A, Janssen PFM, Gommeren W, et al. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Ber1) 124: 57-73.
22. 2 activity (S/D ratio) in plasma. Jpn J Clin Phychopharmacol 6: 1595-1605.
23. Une T, Kurumiya S. 2007. Pharmacological profile of blonanserin. Jpn J Clin Phychopharmacol 10: 1263-1272.